A patient has prescriptions for two inhalers: a bronchodilator and a corticosteroid.
What instruction regarding the administration of these inhalers will the nurse provide to the patient?

This question requires evaluating the efficacy of pain management interventions. By comparing post-intervention assessments against the predefined therapeutic threshold of less than 3 out of 10, the nurse can identify failed goals, indicating the need for a reassessment and modification of the treatment plan.

Choice A rationale

Restlessness and the inability to sleep at 0100 hours are objective clinical indicators of uncontrolled pain. These behaviors demonstrate that the current analgesic regimen is insufficient, confirming that the therapeutic goal of a pain level less than 3 was not achieved.

Choice B rationale

Improved ability to participate in self-care with minimal assistance is a positive clinical indicator of successful pain management. This suggests the patient is functioning better, which supports the conclusion that the pain interventions have effectively contributed to their functional recovery.

Choice C rationale

Obtaining 7.5 hours of uninterrupted sleep is a clear sign that the patient is comfortable and effectively resting. This outcome indicates the analgesic medication is providing the necessary relief to support restorative sleep, confirming that the therapeutic goal was met.

Choice D rationale

Eating breakfast without nausea indicates that the patient is tolerating their medication and is free from the adverse effects or physiological distress associated with uncontrolled pain. This signifies a successful response to the pain management protocol implemented by the nursing staff.

This question tests patient understanding of potassium-sparing diuretics. It requires identifying the need for further education when a patient plans to alter their medication dosage independently, which poses a severe risk of life-threatening electrolyte imbalances, particularly hyperkalemia, in patients prescribed this diuretic therapy.

Choice A rationale

Taking spironolactone with food is recommended as it helps to increase the drug's oral bioavailability and significantly reduces the common gastrointestinal side effects, such as nausea or stomach upset, which are frequently reported by patients during the initial weeks of treatment.

Choice B rationale

Patients must never independently alter their medication dose. Spironolactone acts as an aldosterone antagonist, and self-adjusting the dose can lead to erratic blood pressure control or severe, potentially life-threatening hyperkalemia, which is a significant clinical risk requiring ongoing provider monitoring.

Choice C rationale

Spironolactone can cause hyperkalemia, which significantly increases the risk of cardiac dysrhythmias. Patients are rightly taught to monitor for signs of irregular heartbeats, such as palpitations or skipped beats, and report these concerns immediately to ensure proper cardiovascular safety and monitoring.

Choice D rationale

Salt substitutes often contain potassium chloride, and potassium-rich foods can contribute to dangerous elevations in serum potassium levels. Patients on spironolactone are at a high risk for hyperkalemia (normal range 3.5 to 5.0 mEq/L) and must avoid these dietary sources.